Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
Study limitation reported by the research below: “All participants were Japanese adults; results may not generalize to other ethnic populations given known differences in metabolic risk profiles and BMI thresholds.”